Cardiovascular and metabolic conditions are risk factors for ED and are common among men with ED. The purpose of this study was to assess the safety and effectiveness of, and notably patient satisfaction with, vardenafil treatment in a general population of men with ED, including those with underlying conditions, over a period of 3-12 months. A prospective, multicenter, noninterventional study was carried out in Germany between July 2005 and January 2007. Men aged X18 years (n ¼ 7088) who were prescribed vardenafil for ED, irrespective of previous ED treatment or underlying conditions, were eligible for inclusion. Safety, effectiveness and patient satisfaction data were collected by physician case report forms (CRFs) after 3 months, with optional self-completed patient questionnaires at baseline, 3, 6, 9 and 12 months. The intentto-treat population included 6474 patients, and 1331 patients returned at least one questionnaire. No serious adverse events were related to vardenafil use. CRF data showed that 93.0% of patients reported improved erections after 3 months, with similar rates of improvement among men with underlying conditions. High levels of patient satisfaction with vardenafil regarding effectiveness of treatment, time to onset and duration of action were sustained throughout the study.
Introduction
Erectile dysfunction is defined as the persistent inability to attain and maintain a penile erection sufficient for satisfactory sexual intercourse. 1 The National Health and Social Life Survey published in 1999 reported an ED prevalence rate of 16% in men aged 18-59 years, whereas more recently, the Men's Attitudes to Life Events and Sexuality (MALES) study found similar ED prevalence rates among men aged 20-75 years. 2, 3 Erectile dysfunction of organic origin is most commonly the result of peripheral vascular disease within the penis, resulting in endothelial damage and impaired blood flow. 4 Risk factors for ED are similar to those for cardiovascular disease and include diabetes, hypertension, dyslipidemia, obesity and smoking. 5 Epidemiological evidence linking cardiovascular risk factors to ED has been provided by a number of studies. For example, the MALES study found increased ED prevalence in men with cardiovascular risk factors, 2 whereas a study conducted in France among men seeking treatment for hypertension or diabetes found that ED was present in 61 and 67% of men with these conditions, respectively. 6 The prevalence among men with both conditions was 77%.
According to current American Urological Association and European Association of Urology guidelines, oral PDE5 inhibitors are recommended as first-line therapy for ED. 7, 8 These offer advantages over alternative treatments, being noninvasive and easy to administer. A number of placebo-controlled trials have shown the clinical efficacy of PDE5 inhibitors for the treatment of ED. [9] [10] [11] Prescribing data from Europe and the United States also show that PDE5 inhibitors are patients' treatment of choice.
inhibitors in patients with underlying conditions. Previously, vardenafil was shown to be efficacious and well tolerated in clinical trials of patients with diabetes, 13, 14 hypertension 15, 16 and dyslipidemia, 17 as well as in the Real-Life Safety and Efficacy of vardenafil (REALISE) study, a worldwide noninterventional study that included large numbers of men with ED and cardiovascular and metabolic conditions. 18, 19 This paper presents the data collected in Germany between July 2005 and January 2007. The aim of this study was to assess the safety and effectiveness of, and notably patient satisfaction with, vardenafil treatment in men with ED, including those with underlying cardiovascular and metabolic conditions, under daily life conditions over a period of 3-12 months.
Patients and methods

Study design
ACceptance of Therapy In Vardenafil-treated patients with Erectile dysfunction (ACTIVE) was a prospective, multicenter, noninterventional, observational study investigating the long-term effectiveness of vardenafil for the treatment of ED in a broad population of men in Germany. The only inclusion criteria were age X18 years and a clinical diagnosis of ED. Any previous treatment for ED was permissible, and there were no exclusions relating to underlying conditions. Physicians were instructed to exclude patients with any contraindications to the use of vardenafil in accordance with the local product information. However, if data were received for such patients, they were not excluded from the analysis. The intent-to-treat (ITT) population comprised men taking at least one out of eight (or more) prescribed doses of vardenafil.
Participants were prescribed vardenafil (5, 10 or 20 mg) for on-demand use at the discretion of their physician. The dose could be adjusted by the physician after 3 months, in line with labeling instructions. Patients were instructed not to exceed one dose per day.
For each patient, the study physician collected data in a case report form (CRF) at the initial visit and a routine follow-up visit B3 months after the first dose of vardenafil. In addition, patient questionnaires assessing ED status, course of ED, sexual behavior and relationship with partner were voluntarily returned at baseline, and 3, 6, 9 and 12 months after the first dose of vardenafil.
Effectiveness evaluation
The CRF included questions on patient's perception of improvement in ED ('Did vardenafil treatment improve the erection of the patient?'); whether erectile function improved after the first or cumulative intakes of vardenafil; minimum time interval between vardenafil intake and the start of intercourse; how often the patient was able to complete intercourse successfully; patient satisfaction with effectiveness concerning onset and duration of action; and patient preference for vardenafil compared with their previous ED treatment.
Long-term assessment of effectiveness and patient satisfaction was based on self-completed, optional patient questionnaires. These included questions on: time elapsed from taking vardenafil before the patient could get an erection; duration of action of vardenafil; influence of vardenafil on sex life/ relationship (spontaneity of intercourse); patient acceptance of vardenafil treatment (that is, satisfaction with speed of onset and duration of action); and patient confidence in the effectiveness of vardenafil treatment.
Safety evaluation
Both the ITT and safety populations included all patients. Safety analysis was based on treatmentemergent adverse events (AEs) recorded in the CRF at 3 months, and all AEs reported spontaneously by the physician during the 12-month study period. Patient questionnaires were also assessed using a conservative approach, whereby all AEs occurring among patients taking at least one dose of vardenafil were classed as treatment-emergent AEs. Classification was according to the Medical Dictionary for Regulatory Activities coding, relationship to vardenafil use and frequency. In addition, severity, relation to sexual activity, action taken and outcome were recorded for all AEs.
Statistical analyses
Data analysis was based on the ITT population. Descriptive analyses of the data were carried out using summary statistics for categorical and quantitative data. Continuous data were described by mean and s.d.
Ethics and informed consent
Vardenafil was prescribed for an approved indication within the regular practice of the attending physician. Only data and observations during regular vardenafil therapy were documented and no additional diagnostic or monitoring procedures were applied to patients. Therefore, it was not necessary to seek ethics committee approval or informed consent before the start of the study.
Results
A total of 7088 patients were enrolled in the study, 6474 of whom were eligible for inclusion in the ACTIVE: vardenafil safety, efficacy and acceptance H Sperling et al
ITT/safety population. Reasons for exclusion from the ITT population were (multiple responses possible): initial visit more than 2 days before the start of the study (n ¼ 358); no physician documentation available (n ¼ 140); patient lost to follow-up (n ¼ 71); visit date later than the last return date for CRF (n ¼ 26); no drug intake (n ¼ 14); and documented intake of another PDE5 inhibitor (n ¼ 9). Within the ITT population, 6441 patients (99.5%) attended the follow-up visit at 3 months.
Patients' demographic and clinical characteristics are shown in Table 1 . The majority were white (96.9%) with a mean age of 58.1 years. Physicianassessed severity of ED was moderate for the majority of participants (63.1%), and 84.1% of patients had ED of at least 6 months duration at enrolment. Previous treatment for ED had been received by 26.4% of participants; of these, 55.6% had previously taken sildenafil and 19.6% had taken tadalafil.
Underlying cardiovascular and metabolic conditions associated with ED were common among study participants, the most prevalent being hypertension (diagnosed in 30.7% of patients) (Table 1) . Overall, 72.1% of patients were overweight or obese (body mass index X25 kg m À2 ). Approximately half of the patients were taking concomitant medications, including agents acting on the renin-angiotensin system, b-blocking agents, drugs used in diabetes and antithrombotic agents. A small number of patients (7.1%) were taking medications known to interact with vardenafil, including a-blocking agents.
Vardenafil dosage was not adjusted at the 3-month follow-up visit for 74.0% of patients. In 11.8% of patients, the dose was increased and in 3.0% of patients, the dose was reduced. For the remaining patients (11.2%), data regarding dose adjustment were incomplete. After a 3-month follow-up, 56.7% of patients were taking 20 mg vardenafil, 30.8% of patients received 10 mg vardenafil and 1.9% of patients received 5 mg (for 10.7% of patients, data were missing).
Effectiveness
Physicians' CRFs (assessed after 3 months only). In response to the CRF question 'Has the vardenafil treatment improved the patient's erection?', the answer 'yes' was recorded for 93.0% of patients. When stratified by underlying cardiovascular or metabolic conditions, the improvement rate remained high (Figure 1 ). More than half of the patients (63.4%) reported an improvement in erections after the first dose of vardenafil. At 3-month follow-up, 89.4% of patients stated they were 'always' or 'mostly' able to complete intercourse successfully.
Overall, 38.3% of patients began sexual intercourse within 30 min of taking vardenafil, and 80.8% of patients within 60 min (Figure 2 ). Most patients (92.0%) were documented as being Physicians' assessment of patient satisfaction showed that 91.8% were 'satisfied' or 'very satisfied' with the effectiveness of vardenafil (Figure 3) . Furthermore, 85.6% of patients responded positively when asked by their physician whether they would continue using vardenafil.
The three most common reasons for discontinuation of treatment included a switch to other medication (30.7%), price (30.2%) and AEs (3.6%).
Of those patients who had previously received sildenafil or tadalafil treatment for ED, 76.4 and 64.2%, respectively, stated a preference for vardenafil versus their previous treatment.
Patients' questionnaire (baseline and 3-12 months). Of the 6474 patients in the ITT/safety population, 20.6% voluntarily completed and returned questionnaires. Specifically, 11.7% of patients returned only the first questionnaire, 2.8% of patients provided two questionnaires, three questionnaires were received from 1.6% of patients and four questionnaires were returned by 1.7% of patients. In total, 2.7% of patients returned all the five questionnaires after B12 months.
A comparison of baseline demographic characteristics (age, weight, height and race) found only small differences between patients who completed questionnaires and the ITT/safety population. However, patients who completed questionnaires reported slightly lower alcohol consumption and less smoking. Differences in reported baseline levels of ED were evident, but absolute differences were within a 4% range.
Across all questionnaires, 460% of patients reported having sex more spontaneously during the previous 3 months than before (questionnaire responses: 'a little' or 'definitely' more spontaneously). Patient's confidence in the effectiveness of vardenafil was consistently high throughout the treatment period and increased with the duration of use. The proportion of patients reporting that they were 'pretty' or 'very' confident in the effectiveness of vardenafil remained 470% throughout the 3-to 12-month time period.
Throughout the treatment period, 480% of participants reported that intercourse started within 1 h of taking vardenafil. High levels of patient satisfaction ('pretty' or 'very' satisfied) with how quickly an erection could be achieved were maintained throughout the study. As relatively few patients returned all four post-baseline questionnaires, an average was taken for the last questionnaires received, regardless of time point. Using this approach, 73.4% of patients were satisfied with how quickly an erection could be achieved. Figure 1 Percentage of patients with improved erections within the overall study population (intent-to-treat population) and subgroups of patients with underlying conditions. CHD, coronary heart disease; PVD, peripheral vascular disease. 
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Case report form and patient questionnaire data were comparable, with 93.0% of patients reporting improved erections at follow-up (CRF) versus 86.9% of patients confident in the effectiveness of vardenafil after 12 months of treatment (questionnaire). The majority of patients stated they wished to carry on with vardenafil therapy (CRF, 85.6%; 3-month questionnaire, 76.1%). In addition, an average was taken for the last questionnaires received, regardless of time point. Using this approach, 68.5% of patients wished to carry on with treatment.
Safety evaluation
After 3 months of treatment, vardenafil was judged to be well tolerated (rated by physician as 'satisfied' or 'very satisfied' with tolerability) in 97.9% of patients.
A total of 173 treatment-emergent AEs were documented in 122 patients (1.88%). There was no formal requirement for physicians to assess tolerability and safety after the 3-month observation period, but all patient questionnaires were scanned for comments relating to safety. Of the 173 AEs reported, 10 occurred at more than 3 months after the start of treatment.
The most common AEs are shown in Table 2 . A total of nine serious AEs were reported in seven patients (0.11%): pneumonia, carotid artery stenosis, osteoarthritis, cerebrovascular accident, myocardial infarction, benign prostatic hyperplasia and spinal operation/bladder neck operation. Reasons for classification as serious were 'hospitalization' (n ¼ 6), 'important medical event' (n ¼ 2) and 'lifethreatening' (n ¼ 1). None of these events was deemed related to the use of vardenafil. Twentynine patients (0.45%) discontinued vardenafil treatment due to AEs; two of these AEs were unrelated to vardenafil use. No deaths were reported during the observation period.
Treatment with concomitant medications did not significantly increase the incidence of AEs compared with the overall study population. Incidence rates for AEs related to vardenafil use in patients taking concomitant medications were: a-blocking agents, 1.1%; antihypertensives, 1.4%; antibiotics or antimycotics, none.
Discussion
This study showed that vardenafil is well tolerated and effective for the treatment of ED under realworld conditions in Germany. High levels of patient satisfaction were also observed. Although uncontrolled, the data from this study complement results from clinical trials, and also build on findings from previous noninterventional observational studies, such as the REALISE study. 18, 19 In contrast to clinical trials, the results from this study are based on a sample from everyday clinical practice and thus may be more representative of real-life treatment. The study sample included patients over a wide age range, with ED of differing etiology and severity. Furthermore, the prevalence of underlying cardiovascular and metabolic conditions commonly encountered in men with ED in our study sample showed good concordance with epidemiological studies. For example, 30.7% of men in this study had hypertension, compared with prevalence rates of 32 and 36% in the Cologne 20 and MALES 2 studies, respectively. In this study, the majority of patients responded well to treatment with vardenafil, even though many had underlying cardiovascular and metabolic conditions. This is consistent with the findings from clinical trials of men with ED and diabetes, hypertension and dyslipidemia, and from noninterventional studies. [13] [14] [15] [16] [17] [18] [19] 21 Conditions such as diabetes and severe vascular disease can adversely affect the treatment outcomes in ED, 22 but the beneficial outcome with PDE5 inhibitors is likely to be unaffected, except in patients with advanced vascular impairment. A further consideration is the possibility of adverse drug interactions, as long-term medication is usual among patients with underlying conditions. In this study, after 3 months of treatment, the tolerability of vardenafil was unaffected by the use of concomitant medications. Between 3 and 12 months of treatment, only a few AEs were spontaneously reported, preventing meaningful subgroup analysis. Nevertheless, we found no evidence that the use of vardenafil for ED should be limited by underlying conditions or their associated medications.
In our study, vardenafil improved erections in a very high proportion (B90%) of patients. More than half of patients (B63%) experienced an improvement in erectile function after just one dose of vardenafil, and approximately half engaged in sexual intercourse within 30 min of taking vardenafil. Such success rates are important for patient confidence and compliance with treatment, 23 and 19 whereas in the ReliabilityVardenafil for Erectile Dysfunction I (RELY-I) study, first-dose penetration success rates ranged from 75 to 84% for patients with diabetes, dyslipidemia and hypertension. 23 Further placebo-controlled studies have shown the rapid onset of action of vardenafil, with more than 50% of participants achieving erections within 25 min, 24 and as rapidly as 15 min. 25 The incidence of AEs in this study was low and comparable with previous studies. The majority of AEs related to vardenafil use were consistent with the side-effect profile of PDE5 inhibition. 26 In addition to confirming the safety and effectiveness of vardenafil in daily clinical practice, our study showed very high levels of patient satisfaction. Physicians reported that 480% of patients wished to continue with vardenafil treatment after the initial 3-month phase of the study. In the last set of questionnaires received (irrespective of time point), 68.5% of patients wished to continue with vardenafil treatment. Among patients previously receiving PDE5 inhibitor treatment for ED, 460% preferred vardenafil to their previous treatment.
There are few comparisons of patient preference for vardenafil versus other treatments, but one study showed noninferiority of vardenafil compared with sildenafil. 27 In the present study, at least threequarters of patients indicated that they had confidence in the effectiveness of vardenafil. High levels of patient confidence with vardenafil have been shown in a pooled analysis of three placebocontrolled studies using the Treatment Satisfaction Scale. 28 After 12 weeks of treatment, least squares mean scores for confidence to complete sexual activity more than doubled from baseline for those men taking vardenafil (60.8 versus 27.4), compared with men taking placebo (32.5 versus 26.4). In ED, treatment confidence relates to a patient's sexual confidence in terms of their ability to obtain and keep an erectionthis, in turn, has been shown to be an important determinant of patient-rated effectiveness. 29 Although this study offers valuable insights into the real-world effectiveness of vardenafil, it has some limitations, the principal being the voluntarily self-completed patient questionnaire and small proportion of patients returning all the five questionnaires. This introduces the possibility of selection bias due to a greater likelihood of obtaining questionnaires from those patients getting the most benefit from treatment. Further, it should be noted that physician's data only refer to the 3-month time point following initiation of treatment, with longerterm data derived only from the patient questionnaire, spontaneous reports and a few CRFs where the last visit was conducted more than 3 months after the start of treatment. However, 3-month and longer-term data were generally consistent, for example, in baseline measurements and in the assessment of improvement of erection.
Conclusion
In this noninterventional study performed under reallife conditions, with patients having different ED etiologies and underlying medical conditions (including hypertension, diabetes and lipid metabolism disorder), vardenafil was shown to be well tolerated and highly effective for the treatment of ED, with the majority of patients reporting beneficial improvements in erectile function, and associated high levels of satisfaction and confidence with treatment.
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